Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.29 - $10.25
Previous CloseN/A
Volume24.60K
Average Volume (3M)122.45K
Market Cap
$187.69M
Enterprise Value$354.51M
Total Cash (Recent Filing)$55.45M
Total Debt (Recent Filing)$37.13M
Price to Earnings (P/E)―
Beta3.18
Next Earnings
May 12, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding55,612,240
10 Day Avg. Volume142,691
30 Day Avg. Volume122,453
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.97
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.68
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$11.50Price Target Upside236.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Foghorn Therapeutics News
PremiumCompany Announcements
Foghorn Therapeutics Reports Progress and Financial Stability
PremiumStock Analysis & Ideas
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
PremiumCompany Announcements
Foghorn Therapeutics Advances Drug Development in Oncology
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFHD-909 continues to advance in a Phase 1 trial in SMARCA4-mutated non-small cell lung cancer, capturing significant investor interest.
Pipeline PotentialFoghorn's cash runway of $267.4 million positions the company to execute 3–4 investigational new drug applications, advancing its pipeline significantly.
Strategic CollaborationFoghorn continues to progress its strategic collaboration with Lilly for FHD-909, highlighting potential for innovation and growth.
Bears Say
Clinical BenchmarkThe clinical benefit rate for FHD-286 failed to meet the internal benchmark, leading to its discontinuation and affecting market perception.
Financial PerformanceFoghorn reported collaboration revenue of $3 million, falling short of the $10 million estimate, which could concern investors.
Product DiscontinuationFoghorn's shares have faced pressure following the discontinuation of FHD-286, impacting investor confidence.
---
Ownership Overview
1.32% Insiders
10.88% Mutual Funds
45.40% Other Institutional Investors
37.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.29 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $187.69M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 38 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Mar 06, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.083.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,612,240 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went up 0.444%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
---
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (236.26% Upside)
$11.50 (236.26% Upside)
Hedge Fund Trend
Increased
By 227.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 12.5%
Last 30 Days ▼ 12.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.14%
12-Months-Change
Fundamentals
Return on Equity
322.49%
Trailing 12-Months
Asset Growth
60.32%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
---
FHTX Stock 12 Month Forecast
Average Price Target
$11.50
▲(236.26% Upside)
Technical Analysis
Voyager Therapeutics
―
COMPASS Pathways
―
Lyell Immunopharma
―
CARGO Therapeutics, Inc.
―
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-17.06%
reiterated a buy rating 28 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -17.06% per trade.
---